Biotech plunges 17% as cancer drug fails

BRITISH BIOTECH yesterday added another chapter to its disastrous history when it revealed that its star anti-cancer drug had failed a key clinical trial.

Shares in the beleaguered drug company plunged over 17 per cent to an all-time low of 21.5p after it admitted that Marimastat, one of its most advanced compounds, did not work in the treatment of pancreatic tumours.

Industry experts said the result cast doubts over Marismatat's efficacy and could jeopardise a major part of British Biotech's clinical programme.

The failure of the 400-patient test is a huge blow for the company as it had been predicted over 15 months ago by Andrew Millar, the group's former head of clinical trials.

Mr Millar was sacked in April for looking at confidential data in the trial - a procedure known as "unblinding" - and for expressing concerns to shareholders over the efficacy of marimastat and the anti-pancreatitis compound Zacutex.

The affair sparked a bitter row between Mr Millar and the board, which caused a collapse in the share price from its peak of over pounds 3 and led to the departure of the chief executive, Keith McCullagh.

Mr Millar yesterday said: "We knew this in December 1997. I feel terribly sorry that the right management of a potential new drug was not undertaken."

The new chief executive, Elliot Goldstein, yesterday said that the study's negative results did not spell the end of Marimastat.

He said the test showed that the drug had failed its target of a 16 per cent reduction in death rates compared with an existing drug. However, he said pancreatic cancer was one of the most difficult cancers to treat and that further studies were needed to assess Marimastat's efficacy.

British Biotech was spending around half of its pounds 24m development budget to trial the drug on different forms of cancer in nine other studies and results were expected over the next 12 month. "We are not deciding to quit. The plan is to bring the nine studies to their end," Dr Goldstein said.

Peder Jensen, the development director, denied that the failure of the trials vindicated Dr Millar's actions. He said that when Dr Millar unblinded the study, he could not have predicted the outcome because the data was too scant. "He just happened to be right," Mr Jensen said.

Mr Millar, who is embroiled in a legal case with the company set to be heard in the High Court later this year, rejected the suggestion. "It is a virtual mathematical certainty that this was to happen".

He predicted that the other study he unblinded, a key trial for Zacutex, was also set to fail. The company said it would report on the trial before the end of next month.

City analysts said the result of the trial would prompt investors to reduce their estimates of Marimastat's future earnings. The drug was once hailed as a potential blockbuster with estimated sales of over $1bn a year.

However, a series of setbacks has prompted experts to revise sales predictions to $200m.

Arts and Entertainment
TVShow's twee, safe facade smashed by ice cream melting scandal
News
newsVideo for No campaign was meant to get women voting
Sport
Wayne Rooney talks to the media during a press conference
sport
Arts and Entertainment
tv
PROMOTED VIDEO
News
ebooksAn evocation of the conflict through the eyes of those who lived through it
Sport
Alexis Sanchez celebrates after scoring his first goal for Arsenal in the Champions League qualifier against Besiktas
sportChilean's first goal for the club secures place in draw for Champions League group stages
News
i100
News
Down time: an employee of Google uses the slide to get to the canteen
scienceBosses are inventing surprising ways of making us work harder
Arts and Entertainment
Amis: 'The racial situation in the US is as bad as it’s been since the Civil War'
booksAuthor says he might come back across Atlantic after all
Extras
indybest
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

PMO Analyst - Risk - Banking - London - £350-£400

£350 - £400 per day: Orgtel: PMO Analyst - Risk - Banking - London - £350 - £4...

C# Developer (C#, ASP.NET Developer, SQL, MVC, WPF, Real-Time F

£40000 - £48000 per annum + benefits+bonus+package: Harrington Starr: C# Devel...

C# Swift Payment Developer (C#, ASP.NET, .NET, MVC, Authorize.N

£45000 - £60000 per annum + benefits+bonus+package: Harrington Starr: C# Swift...

DevOps Engineer - Linux, Shell, Bash, Solaris, UNIX, Salt-Stack

Negotiable: Harrington Starr: A fast growing Financial Services organisation b...

Day In a Page

Israel-Gaza conflict: No victory for Israel despite weeks of death and devastation

Robert Fisk: No victory for Israel despite weeks of devastation

Palestinians have won: they are still in Gaza, and Hamas is still there
Mary Beard writes character reference for Twitter troll who called her a 'slut'

Unlikely friends: Mary Beard and the troll who called her a ‘filthy old slut’

The Cambridge University classicist even wrote the student a character reference
America’s new apartheid: Prosperous white districts are choosing to break away from black cities and go it alone

America’s new apartheid

Prosperous white districts are choosing to break away from black cities and go it alone
Amazon is buying Twitch for £600m - but why do people want to watch others playing Xbox?

What is the appeal of Twitch?

Amazon is buying the video-game-themed online streaming site for £600m - but why do people want to watch others playing Xbox?
Tip-tapping typewriters, ripe pongs and slides in the office: Bosses are inventing surprising ways of making us work harder

How bosses are making us work harder

As it is revealed that one newspaper office pumps out the sound of typewriters to increase productivity, Gillian Orr explores the other devices designed to motivate staff
Manufacturers are struggling to keep up with the resurgence in vinyl records

Hard pressed: Resurgence in vinyl records

As the resurgence in vinyl records continues, manufacturers and their outdated machinery are struggling to keep up with the demand
Tony Jordan: 'I turned down the chance to research Charles Dickens for a TV series nine times ... then I found a kindred spirit'

A tale of two writers

Offered the chance to research Charles Dickens for a TV series, Tony Jordan turned it down. Nine times. The man behind EastEnders and Life on Mars didn’t feel right for the job. Finally, he gave in - and found an unexpected kindred spirit
Could a later start to the school day be the most useful educational reform of all?

Should pupils get a lie in?

Doctors want a later start to the school day so that pupils can sleep later. Not because teenagers are lazy, explains Simon Usborne - it's all down to their circadian rhythms
Prepare for Jewish jokes – as Jewish comedians get their own festival

Prepare for Jewish jokes...

... as Jewish comedians get their own festival
SJ Watson: 'I still can't quite believe that Before I Go to Sleep started in my head'

A dream come true for SJ Watson

Watson was working part time in the NHS when his debut novel, Before I Go to Sleep, became a bestseller. Now it's a Hollywood movie, too. Here he recalls the whirlwind journey from children’s ward to A-list film set
10 best cycling bags for commuters

10 best cycling bags for commuters

Gear up for next week’s National Cycle to Work day with one of these practical backpacks and messenger bags
Paul Scholes: Three at the back isn’t working yet but given time I’m hopeful Louis van Gaal can rebuild Manchester United

Paul Scholes column

Three at the back isn’t working yet but given time I’m hopeful Louis van Gaal can rebuild Manchester United
Kate Bush, Hammersmith Apollo music review: A preamble, then a coup de théâtre - and suddenly the long wait felt worth it

Kate Bush shows a voice untroubled by time

A preamble, then a coup de théâtre - and suddenly the long wait felt worth it
Robot sheepdog technology could be used to save people from burning buildings

The science of herding is cracked

Mathematical model would allow robots to be programmed to control crowds and save people from burning buildings
Tyrant: Is the world ready for a Middle Eastern 'Dallas'?

This tyrant doesn’t rule

It’s billed as a Middle Eastern ‘Dallas’, so why does Fox’s new drama have a white British star?